BRIEF-Altamira Therapeutics Provides Update On Nasdaq Listing

Reuters10-05

* ALTAMIRA THERAPEUTICS PROVIDES UPDATE ON NASDAQ LISTING

* ALTAMIRA THERAPEUTICS: GOT ON SEPT 30, A LETTER FROM NASDAQ THAT IT NO LONGER COMPLIED WITH RULE 5550$(A)$(2) OF NASDAQ'S LISTING RULES

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2473994477?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-05 04:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2473994477","market":"us","top_or_hot":-1,"title":"BRIEF-Altamira Therapeutics Provides Update On Nasdaq Listing","media":"Reuters","content":"<html><body><p>Altamira <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Ltd   :</p><p>   * ALTAMIRA THERAPEUTICS PROVIDES UPDATE ON NASDAQ LISTING</p><p>   * ALTAMIRA THERAPEUTICS: GOT ON SEPT 30, A LETTER FROM NASDAQ THAT IT NO LONGER COMPLIED WITH RULE 5550<a href=\"https://laohu8.com/S/A\">$(A)$</a>(2) OF NASDAQ'S LISTING RULES</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Altamira Therapeutics Provides Update On Nasdaq Listing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Altamira Therapeutics Provides Update On Nasdaq Listing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-05 04:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Altamira Therapeutics Ltd   :   * ALTAMIRA THERAPEUTICS PROVIDES UPDATE ON NASDAQ LISTING   * ALTAMIRA THERAPEUTICS: GOT ON SEPT 30, A LETTER FROM NASDAQ THAT IT NO LONGER COMPLIED WITH RULE 5550$(A)$...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2473994477","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473994477","pubTimestamp":1728072135,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Altamira Therapeutics Ltd   :   * ALTAMIRA THERAPEUTICS PROVIDES UPDATE ON NASDAQ LISTING   * ALTAMIRA THERAPEUTICS: GOT ON SEPT 30, A LETTER FROM NASDAQ THAT IT NO LONGER COMPLIED WITH RULE 5550(A)(2) OF NASDAQ'S LISTING RULESSource text for Eikon:    Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","TQQQ":"纳指三倍做多ETF","BK4141":"半导体产品","LU0724618433.USD":"BGF NEW ENERGY \"A4\" (USD) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","CYTO":"Altamira Therapeutics Ltd.","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU1543694498.USD":"法巴水资源基金RH MD Dis","LU0124384867.USD":"贝莱德新能源基金A2","BK4512":"苹果概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","LU1861214812.USD":"Blackrock Future of Transport A2 USD","QID":"纳指两倍做空ETF","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU1861219969.SGD":"Blackrock Future of Transport A2 SGD-H","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","IE00BD6J9T35.USD":"NEUBERGER BERMAN NEXT GENERATION MOBILITY \"A\" (USD) ACC","LU1861215975.USD":"贝莱德新一代科技基金 A2","LU1548497426.USD":"安联环球人工智能AT Acc","LENZ":"Therapeutics","LU1861220033.SGD":"Blackrock Next Generation Technology A2 SGD-H","LU2360107325.USD":"BGF FUTURE OF TRANSPORT \"A4\" (USD) INC","LU0347712357.USD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (USD) ACC",".IXIC":"NASDAQ Composite","BK4567":"ESG概念","SQQQ":"纳指三倍做空ETF","LU1978683503.SGD":"Blackrock Sustainable Energy A2 SGD-H","BK4139":"生物科技","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","QLD":"纳指两倍做多ETF","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","PSQ":"纳指反向ETF","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU2413666699.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"CRH\" (HKDHDG) INC","BK4007":"制药","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","BK4121":"生命科学工具和服务","LU2298322129.HKD":"BGF SUSTAINABLE ENERGY \"A2\" (HKDHDG) ACC","A":"安捷伦科技"},"translate_title":"简介-Altamira Therapeutics提供纳斯达克上市最新信息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"A":1,".IXIC":1,"NDAQ":1,"LENZ":1,"CYTO":0.9,"TQQQ":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"Altamira Therapeutics Ltd   :   * ALTAMIRA THERAPEUTICS PROVIDES UPDATE ON NASDAQ LISTING   * ALTAMIRA THERAPEUTICS: GOT ON SEPT 30, A LETTER FROM NASDAQ THAT IT NO LONGER COMPLIED WITH RULE 5550$(A)$(2) OF NASDAQ'S LISTING RULESSource text for Eikon:    Further company coverage:","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2473994477"}